ProCE Banner Activity

Erdafitinib and Enfortumab Vedotin Sequencing in Patients With FGFR2/3-Altered aUC: UNITE Database Retrospective Analysis

Conference Coverage

A retrospective analysis of efficacy of erdafitinib and enfortumab vedotin in FGFR2/3-altered advanced or metastatic urothelial carcinoma from the UNITE database found that receiving both erdafitinib and enfortumab vedotin regardless of sequence improved OS vs enfortumab vedotin alone.

Released: February 01, 2024


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Exelixis, Inc., and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.


Exelixis, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC